Asensus Surgical to Ring New York Stock Exchange Opening Bell on February 21, 2023
February 09 2023 - 6:55AM
Asensus Surgical, Inc. (NYSE American: ASXC), a medical device
company that is digitizing the interface between the surgeon and
the patient, today announced that President and CEO Anthony
Fernando will be joined by other leaders of the Company to ring the
opening bell of the New York Stock Exchange on February 21, 2023.
On the same day, the Company is hosting an Investor Day.
"We are honored to ring the New York Stock Exchange opening bell
on behalf of the global Asensus Surgical team. Since our listing on
NYSE in 2015, Asensus Surgical has always been dedicated to
innovation, and driving safer and more reliable outcomes for
surgeons, hospitals and patients," said Anthony Fernando, Asensus
Surgical President and CEO. "The bell-ringing ceremony is a
wonderful way to commemorate the Company's significant
accomplishments as we work to usher in a new era of
Performance-Guided Surgery."
February 2023 Investor Day
The Company is hosting an Investor Day on the same day, Tuesday,
February 21, 2023 in New York, NY. The event will begin at 11:30 AM
EST. A live webcast of the conference presentation will be
available online on the investor relations page of the Company’s
website at https://ir.asensus.com/events-and-presentations. Replays
of the webcasts will be archived on the website.
About Asensus Surgical, Inc.
Asensus Surgical, Inc. is digitizing the interface between the
surgeon and patient to pioneer a new era of Performance-Guided
Surgery by unlocking clinical intelligence for surgeons to enable
consistently superior outcomes and a new standard of surgery. This
builds upon the foundation of Digital Laparoscopy with the
Senhance® Surgical System powered by the Intelligent Surgical Unit™
(ISU™) to increase surgeon control and reduce surgical variability.
With the addition of machine vision, augmented intelligence, and
deep learning capabilities throughout the surgical experience, we
intend to holistically address the current clinical, cognitive and
economic shortcomings that drive surgical outcomes and value-based
healthcare. Learn more about Performance-Guided Surgery and Digital
Laparoscopy with the Senhance Surgical System here:
www.senhance.com. Now available for sale in the US, EU, Japan,
Russia, and select other countries. For a complete list of
indications for use, visit: www.senhance.com/indications. For more
information, visit www.asensus.com.
Follow Asensus
Email Alerts: https://ir.asensus.com/email-alerts
LinkedIn:
https://www.linkedin.com/company/asensus-surgical-inc
Twitter: https://twitter.com/AsensusSurgical
YouTube: https://www.youtube.com/c/transenterix
Vimeo: https://vimeo.com/asxc
TikTok: https://www.tiktok.com/@asensus_surgical
INVESTOR CONTACT:
Mark Klausner or Mike Vallie, 443-213-0499
invest@asensus.com
MEDIA CONTACT:
Isabella Rodriguez, 708-833-1572
CG Life
irodriguez@cglife.com
Asensus Surgical (AMEX:ASXC)
Historical Stock Chart
From Mar 2024 to Apr 2024
Asensus Surgical (AMEX:ASXC)
Historical Stock Chart
From Apr 2023 to Apr 2024